Clinical trial
Trastuzumab and Combination Chemotherapy in Treating Patients With Locally…
NCT00005831 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00005831 |
|---|---|
| Title | Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer |
| Official title | Phase II Evaluation of Trastuzumab (Herceptin), Paclitaxel, Carboplatin, and Gemcitabine in the Treatment of Advanced Urothelial Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Bladder Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Squamous Cell Carcinoma of the Bladder, Stage IV Bladder Cancer, Transitional Cell Carcinoma of the Bladder |
| Intervention type | Biological, Drug, Other |
| Interventions | trastuzumab, paclitaxel, carboplatin, gemcitabine hydrochloride, laboratory biomarker analysis |
| Enrollment | 40 |
| Start date | Mar 1, 2000 |
| Primary completion | Aug 1, 2004 |
| First posted | Jan 27, 2003 |
| Last update posted | Jan 14, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: